Actavis’ DUR001-303 phase 3 study of single-dose Dalvance for ABSSSI meets end points
Dalvance is used for treating acute bacterial skin and skin structure infections (ABSSSI) which are caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA). DUR001-303 was